NCT05776823 (PLI-MOUD) is a NA clinical trial of Pharmacist Narcan Training in Opioid Use Disorder, sponsored by University of Arkansas.

Who is sponsoring NCT05776823?

NCT05776823 is sponsored by University of Arkansas.

What drugs are being tested in NCT05776823?

Interventions in NCT05776823: Pharmacist Narcan Training, BIRT, SMC, Substance Use Counselor Narcan Training.

What condition does NCT05776823 study?

NCT05776823 studies Opioid Use Disorder, Overdose.

Is NCT05776823 still recruiting?

NCT05776823 is currently completed. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT05776823: PLI-MOUD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacist-Led Interventions to Increase Access to Medications for Opioid Use Disorders (PLI-MOUD)

Completed NA Last updated 6 April 2026

What this trial tests

NA trial testing Pharmacist Narcan Training in Opioid Use Disorder in 267 participants. Completed in 21 May 2025.

Timeline

5 May 2023

Primary endpoint
21 May 2025

21 May 2025

Quick facts

Lead sponsor	University of Arkansas
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	267
Start date	5 May 2023
Primary completion	21 May 2025
Estimated completion	21 May 2025
Sites	1 location across United States

Drugs / interventions tested

Pharmacist Narcan Training
BIRT
SMC
Substance Use Counselor Narcan Training

Conditions studied

Opioid Use Disorder — all drugs for Opioid Use Disorder →
Overdose — all drugs for Overdose →

Sponsor

University of Arkansas

Who can join

18 and older, any sex, with Opioid Use Disorder or Overdose. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the impact of a pharmacist-led intervention to expand access to medications for opioid use disorder (MOUD) on racial/ethnic differences in opioid-related overdose among individuals diagnosed with opioid use disorder (OUD) currently incarcerated in a carceral setting. In this study, participants will be screened for opioid use, trained to administer Narcan nasal spray, receive motivational counseling and referral to treatment post-release from a carceral setting (a Re-Entry program) into the community.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Opioid Use Disorder

Currently open trials in the same condition.

NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting

Other University of Arkansas trials

Trials by the same sponsor.

NCT07029776 — MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma · Phase 2 · not yet recruiting
NCT07341399 — Essential Amino Acid Supplementation in Adult Spinal Deformity Patients · NA · not yet recruiting
NCT07071766 — Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment · NA · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT06604065 — Essential Amino Acids and Parkinsons Disease · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05776823 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arkansas
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05776823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing